The LMCA saga continued! 🔭In the OCTOBER trial, OCT guided PCI in true LM bifurcations was associated with a non-significant improvement in MACE - following the main trial. 🔥Even tough the LMCA ostium was difficult to visualize, USD in the edge was frequent! #TCT2025

PROCTOR trial: Post-CABG patients with graft failure undergoing PCI of an SVG had a lower 1-year MACE risk than those undergoing PCI of a native vessel. #TCT2025 View the slides here: https://t.co/Gxk0tHMVJw

Revascularization in Ischemic Left Ventricular Dysfunction: a pathophysiology-guided, evidence-based approach Trials of routine coronary revascularization for iLVD have shown neutral results except for a benefit of CABG emerging beyond 5 years from surgery, supporting a

#TCT2025 LBCT Takeaways Thanks to all investigators & authors for advancing our field

Regarding this review, I’m sharing our publication on the V-LA #ECMO configuration in @asaiojournal. Initially inadvertent and not without risks, yet with remarkable potential benefits: https://t.co/Qdj3f4fZX0

iMODERN Trial (NEJM/TCT 2025) In STEMI + multivessel CAD, immediate iFR-guided PCI was not superior to deferred stress CMR-guided PCI at 3 yrs (death/MI/HF HR 0.95). ~44 % iFR positive vs 22 % CMR positive. Stroke 3.7 %→1.3 %. ➡️ Physiology works, but timing may not matter.

Sharing the results of The PROMISE Trial - just released at TCT in San Francisco - investigating the benefit of stratified treatment in MINOCA @RoccoMontone @ehj_ed https://t.co/Np3doQWaYm

https://t.co/w7cWGsvD0R

Whooaaaa ! Competition is here! @CRF #TCT2025

TCT 2025 LATE BREAKING CLINICAL TRIALS: One LINER SUMMARY 📸 AT A GLANCE ⭐️ What a phenomenal scientific meeting! Congratulations to all the presenters & leaders for their innovation, hard work and knowledge sharing. Thank you @TCTConference @TCTMD @crfheart team for a

#TCT2025 @TCTConference @crfheart 10 year results of Noble Trial 🧨PCI vs. CABG: similar all-cause mortality 🧨No difference at 0-5 and 5-10 years 🧨In ACS: PCI associated with lower mortality 🧨SYNTAX score: no association with mortality

SELUTION DeNovo - non inferiority for TVF at 1 yr demonstrated. Randomisation before lesion prep ➡️ 20% DES use in DEB arm ➡️ 50% non inferiority margin of overall tvf in both arms !!!!! ➡️ TVF 4.4 vs 5.3% in des and deb arms This is a landmark moment- analogous to introduction

Game-changing balloon-expandable #TAVR platform MiRus® #Siegel valve 30d EFS presented #TCT2025 by @PradeepYadavMD ! - Rhenium frame nickel free, porcine dry pack tissue with anticalcification - 8F expandable sheath - Short height but high radial strength - PVL skirt -

This is a truly historic moment. The results from this pivotal trial evaluating a fully percutaneous transcatheter mitral valve replacement technology has opened a new treatment option for patients who are not good candidates for surgery or TEER. This is a remarkable milestone

Not all secondary #Mitral #regurgitations are equal. Careful assessment of the mechanism — ventricular vs. atrial, tethering vs. annular dilation — is essential to guide therapy. As @hahn_rt reminds us, precision imaging leads to precision intervention. #TCT2005 @crfheart

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION https://t.co/l36vzx9YiK

#cardiotwitter #TCT2025 our multicenter data on saline vs contrast OCT being presented today by @SanyaChhikara As OCT technology advances, with new systems offering pullback speeds of up to 100 millimeters per second, the data provided in this study become increasingly pertinent

Whoaaaaaa a third time!!

@MayraGuerreroMD ⚖️ TAVR-first or SAVR-first? #TCT2025 🩺 TAVR-first:✅ Lower mortality & stroke rates (1–10 yrs)✅ Less AF, shorter stay, better hemodynamics🫀 SAVR-first:✅ More data on durability & valve-in-valve options✅ Root enlargement possible @crfheart

Whoa the lithotripsy is getting lithotripsied today? #TCT2025 @CRF Us players with CB ‘s and OPN ‘s are having an I told you so moment now!